Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 8/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960953 | 0.90 | CALCRL (0.50) | CALCRLCRBNDDB1RAMP1 | |
| SCHEMBL14560037 | 0.83 | CALCRL (0.58) | CALCRLCRBNDDB1RAMP1 | |
| SCHEMBL12461611 | 0.82 | CALCRL (0.47) | CALCRLCRBNDDB1RAMP1 | |
| SCHEMBL13055192 | 0.81 | CALCRL (0.44) | CALCRL | |
| SCHEMBL12655225 | 0.80 | CALCRL (0.63) | CALCRLCRBNDDB1RAMP1 | |
| SCHEMBL12622674 | 0.80 | CALCRL (0.55) | CALCRLCRBNDDB1RAMP1 | |
| SCHEMBL14518237 | 0.77 | CALCRL (0.60) | CALCRLCRBNDDB1RAMP1 | |
| SCHEMBL13192017 | 0.76 | TDP2 (0.42) | CALCRLCRBN | |
| SCHEMBL380001 | 0.76 | CALCRL (0.41) | CALCRLCRBN | |
| SCHEMBL1727271 | 0.76 | TDP2 (0.42) | CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608627-B1 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1608627-A4 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | disclosed |
| EP-1608627-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004082605-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | BDKRB2, CALCRL, CCKBR | CALCRL 2/4885CRBN 3137/4885DDB1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.